AR038702A1 - USE OF 3-PHENYL-5-ALCOXI-1,3,4-OXADIAZOL-2-SUBSTITUTED WAVES TO PRODUCE MEDICINES WITH AN INHIBITING EFFECT ON PANCREATIC LIPASE - Google Patents

USE OF 3-PHENYL-5-ALCOXI-1,3,4-OXADIAZOL-2-SUBSTITUTED WAVES TO PRODUCE MEDICINES WITH AN INHIBITING EFFECT ON PANCREATIC LIPASE

Info

Publication number
AR038702A1
AR038702A1 ARP030100625A ARP030100625A AR038702A1 AR 038702 A1 AR038702 A1 AR 038702A1 AR P030100625 A ARP030100625 A AR P030100625A AR P030100625 A ARP030100625 A AR P030100625A AR 038702 A1 AR038702 A1 AR 038702A1
Authority
AR
Argentina
Prior art keywords
alkyl
groups
aryl
substituted
alkyloxy
Prior art date
Application number
ARP030100625A
Other languages
Spanish (es)
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of AR038702A1 publication Critical patent/AR038702A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Uso de 3-fenil-5-alcoxi-1,3,4-oxadiozol-2-onas sustituidas para producir medicamentos con un efecto inhibidor sobre la lipasa pancreática. Uso de 3-fenil-5-alcoxi-1,3,4-oxadiazol-2-onas sustituidas y de sus sales y sales de adición de ácidos farmacológicamente aceptables, para producir medicamentos que tengan un efecto inhibidor sobre la lipasa pancreática, PL. Uso de los compuestos de fórmula (1) en la que los radicales tienen los significados especificados, y de sus sales y sales de adición de ácidos farmacológicamente aceptables, para producir un medicamento para la profilaxis o el tratamiento de la obesidad o de la diabetes mellitus del tipo 1 y 2. Reivindicación 1: El uso de 3-fenil-5-alcoxi-1,3,4-oxadiazol-2-onas sustituidas de fórmula (1) en la que los significados son: R1 los grupos alquilo de C1-6, cicloalquilo de C3-9, siendo posible que ambos grupos estén sustituidos una o más veces con los grupos fenilo, alquiloxi de C1-4, S-alquilo de C1-4, N(alquilo de C1-4)2, y el grupo fenilo es posible que a su vez esté sustituido una o más veces con los grupos halógeno, alquilo de C1-4, alquiloxi de C1-4, nitro, CF3; y R2, R3, R4 y R5 son, independientemente uno de otro, hidrogeno o los grupos halógeno, nitro, alquilo de C1-4; alquiloxi de C1-9, que está sustituido con los grupos flúor, arilo de C6-10, amino o alquilo de C1-4-amino; los grupos arilo de C6-10-alquiloxi de C1-4, ariloxi de C6-10, arilo de C6-10, ariloxi de C6-10-alquilo de C1-4, cicloalquilo de C3-8 u O-cicloalquilo de C3-8, cada uno de los cuales puede estar sustituido una, dos o tres veces con los grupos halógeno, CF3, alquiloxi de C1-4 o alquilo de C1-4; los grupos SO2-NH-alquilo de C1-6, opcionalmente sustituidos con un grupo N(alquilo de C1-6)2, o SO2-NH-(2,2,6,6-tetrametilpiperidin-4-il), SO2-NH-cicloalquilo de C3-8, opcionalmente sustituido una o más veces con un grupo alquilo de C1-4, o SO2-N(alquilo de C1-6)2 o COX, 2-oxo-pirrolidin-1-ilo, 2,5-dimetilpirrol-1-ilo o NR6-A-R7, con la condición de que R2, R3, R4 y R5 no sean simultáneamente hidrógeno, con X los grupos O-alquilo de C1-6, NH-alquilo de C1-6, NH-cicloalquilo de C3-8 o N(alquilo de C1-6)2 y el grupo N(alquilo de C1-6)2 también puede ser los grupos pirrolidino, piperidino, morfolino, tiomorfolino, o piperazino, cada uno de los cuales puede estar opcionalmente sustituido con los grupos alquilo de C1-4, bencilo, arilo de C6-10, CO-alquilo de C1-4, CO-arilo de C6-10, CO-O-alquilo de C1-4, SO2-alquilo de C1-4, o SO2-arilo de C6-10; R6 hidrógeno, o los grupos alquilo de C1-4 o arilo de C6-10-alquilo de C1-4, en el que el grupo arilo puede estar sustituido con los grupos halógeno, CF3, alquiloxi de C1-8 o alquilo de C1-4; A un enlace simple, COn, SOn o CONH; n es 1 ó 2; R7 hidrógeno; los grupos alquilo de C1-18 o alquenilo de C2-18, cada uno de los cuales puede estar sustituido de una a tres veces con los grupos alquilo de C1-4, halógeno, CF3, alquiloxi de C1-4, N(alquilo de C1-4)2, -COOH, alquiloxi de C1-4-carbonilo, arilo de C6-12, ariloxi de C6-12, arilo de C6-12-carbonilo, arilo de C6-10-alquiloxi de C1-4, u oxo, en los que el grupo arilo puede a su vez estar sustituido con los grupos halógeno, alquilo de C1-4, aminosulfonilo o metilmercapto; los grupos arilo de C6-10-alquilo de C1-4, cicloalquilo de C5-8-alquilo de C1-4, cicloalquilo de C5-8, arilo de C6-10-alquenilo de C2-6, arilo de C6-10, bifenililo, bifenililo-alquilo de C1-4, indanilo, cada uno de los cuales puede estar sustituido una o dos veces con los grupos alquilo de C1-18, alquiloxi de C1-18, cicloalquilo de C3-8, COOH, hidroxilo, alquilo de C1-4-carbonilo, arilo de C6-10-alquilo de C1-4, arilo de C6-10-alquiloxi de C1-4, ariloxi de C6-10, nitro, ciano, arilo de C6-10, fluorosulfonilo, alquiloxi de C1-6-carbonilo, arilo de C6-10-sulfoniloxi, piridilo, NHSO2-arilo de C6-10, halógeno, CF3 u OCF3, en los que el grupo alquilo puede estar de nuevo sustituido con los grupos alquiloxi de C1-4-carbonilo, CF3 o carboxilo, y el grupo arilo con los grupos halógeno, CF3 o alquiloxi de C1-4; o el grupo Het-(CH2)n-, con r = 0, 1, 2 o 3, y Het = un grupo heterociclo saturado o insaturado de 5-7 miembros que puede estar benzofundido y sustituido con los grupos alquilo de C1-4, arilo de C6-10, halógeno, alquiloxi de C1-4, alquiloxi de C1-4-carbonilo, arilo de C6-10-alquilo de C1-4, arilo de C6-10-alquilo de C1-4-mercapto, o nitro, en el que el grupo arilo benzofundido puede a su vez estar sustituido con los grupos halógeno, alquiloxi de C1-4 o CF3, y el grupo alquilo en el grupo arilalquilo con los grupos metoxi y CF3, y sus sales y sales de adición de ácidos farmacológicamente aceptables, para producir un medicamento con un efecto inhibidor sobre la lipasa pancreática.Use of substituted 3-phenyl-5-alkoxy-1,3,4-oxadiozol-2-ones to produce drugs with an inhibitory effect on pancreatic lipase. Use of substituted 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-ones and their pharmacologically acceptable acid salts and addition salts, to produce medicaments having an inhibitory effect on pancreatic lipase, PL. Use of the compounds of formula (1) in which the radicals have the specified meanings, and their pharmacologically acceptable salts and addition salts, to produce a medicament for the prophylaxis or treatment of obesity or diabetes mellitus of type 1 and 2. Claim 1: The use of substituted 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-ones of formula (1) in which the meanings are: R1 C1-alkyl groups -6, C3-9 cycloalkyl, it being possible that both groups are substituted one or more times with the phenyl, C1-4 alkyloxy, S-C1-4 alkyl, N (C1-4 alkyl) 2 groups, and the phenyl group may in turn be substituted one or more times with the halogen groups, C1-4 alkyl, C1-4 alkyloxy, nitro, CF3; and R2, R3, R4 and R5 are, independently of one another, hydrogen or the halogen, nitro, C1-4 alkyl groups; C1-9 alkyloxy, which is substituted with the fluorine, C6-10 aryl, amino or C1-4-amino alkyl groups; C6-10-C 1-10 alkyloxy, C6-10 aryloxy, C6-10 aryl, C6-10 aryloxy-C 1-4 alkyl, C3-8 cycloalkyl or C3- O-cycloalkyl groups 8, each of which may be substituted once, twice or three times with the halogen, CF3, C1-4 alkyloxy or C1-4 alkyl groups; SO2-NH-C1-6 alkyl groups, optionally substituted with an N (C1-6 alkyl) 2 group, or SO2-NH- (2,2,6,6-tetramethylpiperidin-4-yl), SO2- C3-8 NH-cycloalkyl, optionally substituted one or more times with a C1-4 alkyl group, or SO2-N (C1-6 alkyl) 2 or COX, 2-oxo-pyrrolidin-1-yl, 2, 5-dimethylpyrrol-1-yl or NR6-A-R7, with the proviso that R2, R3, R4 and R5 are not simultaneously hydrogen, with X the C1-6 O-alkyl groups, NH- C1-6 alkyl , C3-8 or N-cycloalkyl (C1-6 alkyl) 2 and the N (C1-6 alkyl) 2 group may also be the pyrrolidino, piperidino, morpholino, thiomorpholino, or piperazino groups, each which may be optionally substituted with the groups of C1-4 alkyl, benzyl, C6-10 aryl, CO-C1-4 alkyl, CO-C6-10 aryl, CO-O-C1-4 alkyl, SO2- C1-4 alkyl, or C2-10 SO2-aryl; R6 hydrogen, or the C1-4 alkyl or C6-10 aryl-C1-4 alkyl groups, in which the aryl group may be substituted with the halogen, CF3, C1-8 alkyloxy or C1- alkyl groups 4; To a simple bond, COn, SOn or CONH; n is 1 or 2; R7 hydrogen; C1-18 alkyl or C2-18 alkenyl groups, each of which may be substituted one to three times with C1-4 alkyl, halogen, CF3, C1-4 alkyloxy groups, N (alkyl of C1-4) 2, -COOH, C 1-4 alkyloxy, C6-12 aryl, C6-12 aryloxy, C6-12 carbonyl aryl, C6-10 arylC 1-4 alkyloxy, or oxo, in which the aryl group may in turn be substituted with the halogen, C1-4 alkyl, aminosulfonyl or methylmercapto groups; C6-10-C 1-4 alkyl, C5-8 cycloalkyl-C 1-4 alkyl, C5-8 cycloalkyl, C6-10 aryl-C2-6 alkenyl, C6-10 aryl groups, biphenyl, biphenyl-C1-4 alkyl, indanyl, each of which may be substituted once or twice with the C1-18 alkyl, C1-18 alkyloxy, C3-8 cycloalkyl, COOH, hydroxyl, alkyl groups C1-4-carbonyl, C6-10 aryl-C1-4 alkyl, C6-10 aryl-C1-4 alkyloxy, C6-10 aryloxy, nitro, cyano, C6-10 aryl, fluorosulfonyl, alkyloxy of C1-6-carbonyl, C6-10-sulfonyloxy aryl, pyridyl, C6-10 NHSO2-aryl, halogen, CF3 or OCF3, in which the alkyl group can be substituted again with C1-4 alkyloxy groups -carbonyl, CF3 or carboxyl, and the aryl group with halogen, CF3 or C1-4 alkyloxy groups; or the group Het- (CH2) n-, with r = 0, 1, 2 or 3, and Het = a saturated or unsaturated 5-7 membered heterocycle group that may be benzofused and substituted with C1-4 alkyl groups , C6-10 aryl, halogen, C1-4 alkyloxy, C1-4 alkyloxycarbonyl, C6-10 aryl-C1-4 alkyl, C6-10 aryl-C1-4-mercapto alkyl, or nitro, in which the benzofused aryl group may in turn be substituted with the halogen, C1-4 alkyloxy or CF3 groups, and the alkyl group in the arylalkyl group with the methoxy and CF3 groups, and their salts and addition salts of pharmacologically acceptable acids, to produce a drug with an inhibitory effect on pancreatic lipase.

ARP030100625A 2002-02-28 2003-02-26 USE OF 3-PHENYL-5-ALCOXI-1,3,4-OXADIAZOL-2-SUBSTITUTED WAVES TO PRODUCE MEDICINES WITH AN INHIBITING EFFECT ON PANCREATIC LIPASE AR038702A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10208986A DE10208986A1 (en) 2002-02-28 2002-02-28 Use of substituted 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-one for the production of medicaments with an inhibitory effect on the pancreatic lipase

Publications (1)

Publication Number Publication Date
AR038702A1 true AR038702A1 (en) 2005-01-26

Family

ID=27740557

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030100625A AR038702A1 (en) 2002-02-28 2003-02-26 USE OF 3-PHENYL-5-ALCOXI-1,3,4-OXADIAZOL-2-SUBSTITUTED WAVES TO PRODUCE MEDICINES WITH AN INHIBITING EFFECT ON PANCREATIC LIPASE

Country Status (20)

Country Link
EP (1) EP1482929A1 (en)
JP (1) JP2005519079A (en)
KR (1) KR20040101250A (en)
CN (1) CN1638766A (en)
AR (1) AR038702A1 (en)
AU (1) AU2003210292A1 (en)
BR (1) BR0308045A (en)
CA (1) CA2477005A1 (en)
CO (1) CO5611144A2 (en)
DE (1) DE10208986A1 (en)
HR (1) HRP20040783A2 (en)
HU (1) HUP0500093A2 (en)
IL (1) IL163719A0 (en)
MA (1) MA27173A1 (en)
MX (1) MXPA04007480A (en)
NO (1) NO20044091L (en)
PL (1) PL371310A1 (en)
RU (1) RU2004128932A (en)
TW (1) TW200400026A (en)
WO (1) WO2003072098A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005264988B2 (en) 2004-06-17 2011-09-22 Cytokinetics, Inc. Substituted urea derivatives for treating cardiac diseases
AU2005298692A1 (en) 2004-10-25 2006-05-04 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising CB1 cannabinoid receptor antagonists and potassium channel openers for the treatment of diabetes mellitus type I, obesity and related conditions
TW200808321A (en) 2005-12-15 2008-02-16 Cytokinetics Inc Certain chemical entities, compositions and methods
US7825120B2 (en) 2005-12-15 2010-11-02 Cytokinetics, Inc. Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
US7989455B2 (en) 2005-12-19 2011-08-02 Cytokinetics, Inc. Compounds, compositions and methods
US7923462B2 (en) * 2007-12-25 2011-04-12 Kissei Pharmaceutical Co., Ltd. Catechol derivative, pharmaceutical composition containing the same, use of the catechol derivative, and use of the pharmaceutical composition
TW201028406A (en) 2008-12-23 2010-08-01 Bial Portela & Ca Sa 5-O-substituted 3-N-aryl-1,3,4-oxadiazolones for medical use
CN103086859B (en) * 2011-11-08 2015-11-11 清华大学 2,4-dihydroxyl-5,6-replaces-1-halogeno-benzene derivative, its synthetic method and application thereof
WO2019040992A1 (en) * 2017-09-01 2019-03-07 Curtin University Synthetic derivatives of oleoyl-lysophosphatidylinositol (oleolyl-lpi) and uses thereof
CN109879839B (en) * 2019-03-12 2023-04-25 沈阳大学 6-piperazinemethyl-7-hydroxy benzofuran compound and medical application thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19942354A1 (en) * 1999-09-04 2001-03-08 Aventis Pharma Gmbh Substituted 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-one, their manufacture and use in medicinal products
RU2281283C2 (en) * 2000-03-07 2006-08-10 Санофи-Авентис Дойчланд Гмбх Substituted 3-phenyl-5-alkoxy-1,3,4-oxadiazole-2-ones and their using for inhibition of activity of hormone-sensitive lipase

Also Published As

Publication number Publication date
EP1482929A1 (en) 2004-12-08
DE10208986A1 (en) 2003-09-11
BR0308045A (en) 2004-12-21
HRP20040783A2 (en) 2005-04-30
JP2005519079A (en) 2005-06-30
CO5611144A2 (en) 2006-02-28
CN1638766A (en) 2005-07-13
PL371310A1 (en) 2005-06-13
MA27173A1 (en) 2005-01-03
TW200400026A (en) 2004-01-01
WO2003072098A1 (en) 2003-09-04
NO20044091L (en) 2004-09-27
MXPA04007480A (en) 2004-11-10
AU2003210292A1 (en) 2003-09-09
IL163719A0 (en) 2005-12-18
CA2477005A1 (en) 2003-09-04
HUP0500093A2 (en) 2005-04-28
KR20040101250A (en) 2004-12-02
RU2004128932A (en) 2005-04-10

Similar Documents

Publication Publication Date Title
RU2424240C2 (en) Antibacterial piperidine derivatives
AR038702A1 (en) USE OF 3-PHENYL-5-ALCOXI-1,3,4-OXADIAZOL-2-SUBSTITUTED WAVES TO PRODUCE MEDICINES WITH AN INHIBITING EFFECT ON PANCREATIC LIPASE
AR043154A1 (en) SUBSTITUTED DERIVATIVES WITH NITROGEN HEXAHIDRO-PIRAZINO [1,2-A] PIRIMIDIN-4,7-DIONA, PROCEDURES FOR PREPARATION AND USE AS MEDICATIONS
AR067674A1 (en) USEFUL PIRAZOL DERIVATIVES FOR TREATMENT WITH A CCR2 RECEIVER ANTAGONIST
RU2000128036A (en) AMIDINUM COMPOUNDS
AR048691A1 (en) COMPOUNDS WITH ALQUINO STRUCTURE WITH MCH ANTAGONIST ACTION AND MEDICINES CONTAINING THESE COMPOUNDS
NI201000108A (en) CARBAMOYL COMPOUNDS AS INHIBITORS OF DGAT1 190
AR086977A1 (en) USEFUL NITROGEN HETEROCICLIC DERIVATIVES FOR THE TREATMENT OF CANCER AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
AR068639A1 (en) BIARILO DERIVATIVES
CO5640152A2 (en) PHARMACEUTICAL COMPOSITIONS FOR INHIBITORS OF THE PROTEASE OF THE VIRUS OF HEPATITIS C
AR048974A1 (en) SUBSTITUTED DERIVATIVES OF OXAZOL-BENZOISOTIAZOL DIOXIDE AND PHARMACEUTICAL COMPOSITIONS.
AR018187A1 (en) DERIVATIVES OF 1,4-DIHIDRO-1,3-DIAZINS AND 3,4-DIHIDRO-1,3-DIAZINS, PROCEDURE FOR PREPARATION, MEDICINES, PROCEDURE FOR THE PRODUCTION OF THE SAME AND THE USE OF THE SAME FOR THE PRODUCTION OF MEDICINES
AR051094A1 (en) HETEROCICLIC DERIVATIVES AND THEIR USE AS INHIBITORS OF ESTEAROIL-COA DESATURASA
AR047516A1 (en) ACID DERIVATIVES 7-PHENYLAMINO-4-QUINOLONA-3-CARBOXILICO, PROCESSES FOR PREPARATION AND USE AS MEDICATIONS
AR055959A1 (en) ESPIRO DERIVATIVES FOR THE MODULATION OF CRTH2 ACTIVITY
AR040409A1 (en) HISTONE DEACETILASE INHIBITORS
AR042024A1 (en) PHARMACEUTICAL COMPOUNDS DERIVED FROM PIRIDONA, PIRIMIDONA AND PIRAZINONA
AR041734A1 (en) ALKIN COMPOUNDS WITH ANTAGONIC EFFECT OF HCM AND MEDICINES CONTAINING THESE COMPOUNDS
AR049956A1 (en) DERIVATIVES OF 1,3 - OXAZOLIDIN - 2 - ONA AS CETP INHIBITORS AND LAD-C LEVEL ELEVATORS; PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE IN THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF ATEROSCLEROSIS.
AR082015A1 (en) METROXYPHENYL DERIVATIVES HETEROCICLICALLY SUBSTITUTED WITH AN OXO GROUP, PROCEDURES FOR THE PREPARATION AND USE OF THE SAME AS MEDICATIONS
AR018915A1 (en) INHIBITORS OF DIACIL HYDRAZINIC PROTEASES, PHARMACEUTICAL COMPOSITION THAT INCLUDE IT, USES OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT, A MANUFACTURING MANUFACTURE OF SUCH COMPOUNDS
AR040477A1 (en) HETEROCICLICALLY SUBSTITUTED BENZOILUREAS, PROCEDURE FOR PREPARATION AND USE AS PHARMACOS
AR055620A1 (en) CICLOALCANO-CARBOXAMIDAS DERIVATIVES
AR062426A1 (en) USEFUL HETEROCICLICAL COMPOUNDS TO PREPARE MEDICATIONS USED IN PAIN THERAPY.
AR077463A1 (en) IMIDAZO DERIVATIVES [1, 2 - A] PIRAZINA AND ITS USE IN MEDICINES FOR THE TREATMENT OF PARASITARY DISEASES

Legal Events

Date Code Title Description
FB Suspension of granting procedure